A phase II trial has also been conducted assessing the efficacy of AKB-9778 alone or in combination with ranibizumab, a VEGF-neutralizing antibody, in patients with diabetic macular edema (DME) [47]. The gene discussed is VEGFA; the disease is diabetic macular edema.